Original articleHidradenitis suppurativa is a systemic disease with substantial comorbidity burden: A chart-verified case-control analysis

BackgroundHidradenitis suppurativa (HS) is a chronic inflammatory disease involving intertriginous skin. Previous epidemiologic studies have been limited by small sample size.ObjectiveWe sought to describe the prevalence and comorbidities of HS in a large patient care database.MethodsIn this retrospective case-control study, we chart-validated all patients within a hospital database who received at least 1 billing code for HS between 1980 and 2013. Verified cases were matched with controls based on age, gender, and race. Prevalences of a priori selected comorbidities were compared between HS and control groups.ResultsA total of 2292 patients at Massachusetts General Hospital received at least 1 code for HS. A total of 1776 cases had a validated diagnosis of HS, yielding a prevalence of 0.08%. In unadjusted analysis, all comorbidities were diagnosed significantly more in HS compared with control including (in rank order of likelihood): smoking, arthropathies, dyslipidemia, polycystic ovarian syndrome, psychiatric disorders, obesity, drug dependence, hypertension, diabetes, thyroid disease, alcohol dependence, and lymphoma (all P < .01).LimitationsControl subjects were not validated for absence of HS and comorbidity validation was not performed for either group.ConclusionsOur results highlights the high comorbidity burden of patients with HS compared with matched control subjects.